



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com


www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

CTCE 9908 acetate

Chemical Properties

CAS No. :
Formula: C88H151N27O25
Molecular Weight: 1987.31
Appearance: no data available
Storage: keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	CTCE 9908 acetate is an antagonist of CXCR4 and inhibits migration in CXCR4-expressing ovarian cancer cells.
Targets(IC50)	CXCR
In vitro	CTCE 9908 acetate inhibited ovarian cancer cell migration to CXCL12, but on longer incubation, caused cell death in CXCR4-positive cells. CTCE 9908 acetate did not cause apoptosis or cellular senescence, but induced multinucleation, G(2)-M arrest, and abnormal mitosis in ovarian cancer cells. CTCE 9908 acetate deregulated DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G(2)-M phases of the cell cycle. Combination treatment of CTCE 9908 acetate and the drug paclitaxel led to an additive cytotoxicity that also involved mitotic catastrophe[1].
In vivo	In dosing experiment of CTCE 9908 acetate in the PyMT mouse model, increasing doses of CTCE 9908 acetate alone slowed the rate of tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg of CTCE 9908 acetate (p = 0.005). Expression levels of VEGF were also found to be reduced by 42% with CTCE 9908 acetate (p = 0.01). In combination with docetaxel, CTCE 9908 acetate administration decreased tumor volume by 38% (p = 0.02), an effect that was greater than that observed with docetaxel alone. In combination with DC101, CTCE 9908 acetate also demonstrated an enhanced effect compared to DC101 alone, with a 37% decrease in primary tumor volume (p = 0.01) and a 75% reduction in distant metastasis (p = 0.009). In combination with docetaxel or an anti-angiogenic agent, the anti-tumor and anti-metastatic effects of CTCE 9908 acetate were markedly enhanced[2].

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.5032 mL	2.516 mL	5.0319 mL
5 mM	0.1006 mL	0.5032 mL	1.0064 mL
10 mM	0.0503 mL	0.2516 mL	0.5032 mL
50 mM	0.0101 mL	0.0503 mL	0.1006 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481